Trop-2 expression in non–small cell lung cancer
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0321555 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Peiwen Kuo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California, United States of America. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antigens, Neoplasm, Cell Adhesion Molecules. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in non–small cell lung cancer (NSCLC) and has become an attractive target for antibody-drug conjugates (ADCs). ADC tumor target expression is essential in investigating the predictive value of Trop-2 and Trop-2 ADC efficacy. Although Trop-2 mRNA expression in NSCLC has been described, protein-level expression is poorly understood. We investigated Trop-2 expression landscape across multiple data and sample sets to characterize mRNA expression and address the gap in protein-expression profiling. Trop-2 expression was analyzed using available mRNA, mutation, and protein data in three datasets: (1) The Cancer Genome Atlas (TCGA) included clinical-pathological and survival data in NSCLC adenocarcinoma and squamous cell carcinoma; (2) sample set 1 (adenocarcinoma) and (3) sample set 2 (adenocarcinoma, squamous cell carcinoma) underwent sequencing and immunohistochemistry for Trop-2 RNA, protein (Robust Prototype Assay, SP295 clone) and mutation analysis. Trop-2 was highly expressed in NSCLC and expression was similar in adenocarcinoma and squamous cell carcinoma and across baseline characteristics including patient age, sex, and tumor stage. Trop-2 expression was not associated with clinically relevant genetic alterations. Trop-2 was not a prognostic factor in NSCLC (TCGA survival data). High Trop-2 expression in NSCLC was independent of evaluated baseline characteristics, histology, and driver alterations. Trop-2 protein expression at any level was observed in 82% to 90% of NSCLC across sample sets; similar proportions of adenocarcinoma and squamous cell carcinoma expressed Trop-2. These data support broad Trop-2 ADC use in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California, United States of America.
- Gilead Sciences, Inc., Morris Plains, New Jersey, United States of America.
ORCID-Profile: Peiwen Kuo, Juliane M Jürgensmeier
Förderung
- Gilead Sciences
Zitieren
APA
Kuo, P., Elboudwarej, E., Zavodovskaya, M., Lin, K. W., Lee, C. V., Diehl, L., Patel, J., Mekan, S., & Jürgensmeier, J. M. (2025). Trop-2 expression in non–small cell lung cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0321555
Vancouver
Kuo P, Elboudwarej E, Zavodovskaya M, Lin KW, Lee CV, Diehl L, et al. Trop-2 expression in non–small cell lung cancer. PLOS ONE. 2025. doi:10.1371/journal.pone.0321555
BibTeX
@article{Kuo2025,
author = {Kuo, Peiwen and Elboudwarej, Emon and Zavodovskaya, Marianna and Lin, Kai-Wen and Lee, Chingwei V and Diehl, Lauri and Patel, Jilpa and Mekan, Sabeen and Jürgensmeier, Juliane M},
title = {Trop-2 expression in non–small cell lung cancer},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0321555}
}
EUVIMED